Skip to main content

Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)

CBE ID
0070e
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
Next Maintenance Cycle
Spring 2026
1.6 Measure Description

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy

    Measure Specs
      General Information
      1.7 Measure Type
      1.3 Electronic Clinical Quality Measure (eCQM)
      1.9 Care Setting
      1.14 Numerator

      Patients who were prescribed beta-blocker therapy

      1.15 Denominator

      All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior (within the past 3 years) MI or a current or prior LVEF <40%

      Exclusions

      Denominator Exceptions:
      Documentation of medical reason(s) for not prescribing beta-blocker therapy (e.g., allergy, intolerance, other medical reasons).

      Documentation of patient reason(s) for not prescribing beta-blocker therapy (e.g., patient declined, other patient reasons).

      Documentation of system reason(s) for not prescribing beta-blocker therapy (e.g., other reasons attributable to the health care system).

      Most Recent Endorsement Activity
      Endorsed Cardiovascular Spring Cycle 2019
      Initial Endorsement
      Last Updated
      Steward Organization
      American Heart Association
      Steward POC email
      kathie.thomas@heart.org
      Steward Organization Copyright

      Copyright 2019 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.

                Use
                Planned Use
                6.1.2 Current or Planned Use(s)
                6.1.3 Current Use(s)
                  Public Comments